Demethylating agents in myeloid malignancies.
2008
Purpose of Review
Two demethylating agents are approved in myelodysplastic syndromes (MDS): 5-azacitidine and 5-aza-2′-deoxycitidine (decitabine). These drugs are structurally related and induce DNA hypomethylation. Aberrant DNA methylation is associated with gene silencing. It is proposed that hypomethylating agents work by inducing re-expression of epigenetically silenced genes. Here, we provide an up-to-date summary of the clinical experience with these drugs.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
99
Citations
NaN
KQI